The U.S. Food and Drug Administration issued a warning to healthcare providers against administering the malaria drug hydroxychloroquine or chloroquine in combination with Gilead Sciences’ experimental COVID-19 drug, remdesivir.

The FDA proposed new health warnings for cigarette packages and ads due to small size and lack of an image in current warnings.